Key Profile Information
Personal and Educational Background
Dr. Daniela Brunner holds the dual roles of Chief Innovation Officer (CIO) and Chief Technology Officer (CTO) at PsychoGenics Inc. She earned her Ph.D. at Cambridge University (UK) and completed her postdoctoral training at Columbia University (USA). Born in Argentina, Dr. Brunner has been with PsychoGenics since 1999.
Professional Experience
At PsychoGenics, Dr. Brunner has been pivotal in the development of preclinical tests for various cognitive and neurodegenerative conditions, autistic disorders, and more. A significant part of her contribution includes the conception and development of PsychoGenics' SmartCube® system, an advanced AI-based phenotypic platform designed to predict therapeutic potential for neuropsychiatric disorders. This innovation leverages machine learning and computer vision technologies in high-throughput drug discovery.
Notable Achievements
Dr. Brunner's work has garnered her significant recognition, including the Great Minds in STEM Scientist of the Year Award (2021). Her leadership in AI-driven analytical technologies and her strategic direction in phenotypic drug discovery have led to the identification and development of several promising drug candidates, such as SEP-363856 (Ulotaront) for schizophrenia, now in Phase 3 trials in partnership with Sunovion.
Leadership and Vision
Dr. Brunner's role extends beyond traditionally-defined drug discovery approaches. She founded Early Signal Foundation and ScienceForward LLC, which focus on integrating digital technologies into human health solutions. She has also been instrumental in collaborating with non-profit organizations such as the Tuberous Sclerosis Alliance, Children’s Tumor Foundation, and Cohen Veterans Bioscience.
Current Projects and Initiatives
Under her guidance, PsychoGenics has continued to innovate with AI-enabled platforms like eCube™. These platforms are integral to the company's strategy of reducing the time and cost of drug discovery processes while improving the probability of identifying novel drug candidates with unique mechanisms of action suitable for treating neuropsychiatric and other CNS disorders.
Public Engagement and Influence
Dr. Brunner maintains an active presence on professional platforms such as LinkedIn, where she engages with the scientific community through posts and articles on advancements in AI-driven drug discovery and the necessity of new treatments in fields like neuropsychiatry.
Relevant Posts:
- Apr 12, 2023: Discussed AI-enabled polypharmacology's future in drug discovery.
- LinkedIn Profile: Showcases a robust network with 500+ professional connections, emphasizing her influence and connectivity within the biotech industry.
Personal Interests
Beyond her professional achievements, Dr. Brunner enjoys photography and painting, and practices traditional martial arts disciplines such as Kobudo and Iaijutsu.
Contact Information
For collaboration opportunities or more information, Dr. Emer Leahy, President & CEO of PsychoGenics Inc, can be contacted at (914) 406-8008 or emer.leahy@psychogenics.com.
_PsychoGenics' Homepage: [www.psychogenics.com](http://www.psychogenics.com)_
